Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
In addition to its weight-management indication, FDA has also authorized Wegovy to reduce the risk of certain major cardiovascular events in qualifying adults with overweight or obesityan important clinical benefit to discuss with your clinician as you consider therapy
El estudio SURPASS-2 demostr que tirzepatide 15 mg produjo mayor reduccin de A1C (-2.46% vs -1.86%) y prdida de peso (-12.4 kg vs -6.2 kg) comparado con semaglutide 1 mg a las 40 semanas
Circadian rhythms in glutathione and glutathione-S transferase activity of rat liver [PMID: 1380339] Laboratory literature summary: Circadian rhythms in glutathione and glutathione-S transferase activity of rat liver
Other Benefits Significant weight loss Appetite suppression Slows digestion Improves insulin sensitivity Dual mechanism (GLP-1 & GIP agonist) Supports metabolic health Reduces risk of obesity-related conditions Non-surgical solution Convenient & easy to use Possible Side Effects Nausea Vomiting Diarrhea Constipation Abdominal discomfort Decreased appetite Fatigue Dizziness Injection site reactions Low blood sugar (especially in diabetics) Other drugs used for weight loss: Naltrexone HCl and Bupropion (Contrave) Contrave (also called naltrexone HCL or bupropion HCL) is made up of two medications: naltrexone HCL and bupropion HCL
![Cardiovascular disease continuum-GLP-1 action. Adapted from [46]](https://www.researchgate.net/publication/357072789/figure/fig1/AS:1146405179654167@1650335702879/Cardiovascular-disease-continuum-GLP-1-action-Adapted-from-46.png)
